Grant of Interim Extension of the Term of U.S. Patent No. 4,567,264; Ranolazine, 32761 [05-11176]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 107 / Monday, June 6, 2005 / Notices
Patent Ext., P.O. Box 1450, Alexandria,
VA 22313–1450; by fax marked to her
attention at (571) 273–7744; or by e-mail
to Karin.Ferriter@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On May 4, 2005, Intarcia
Therapeutics, Inc., on behalf of patent
owner Schering Aktiengesellschaft,
timely filed an application under 35
U.S.C. 156(d)(5) for a second interim
extension of the term of U.S. Patent No.
4,591,585. The patent claims the
product atamestane. The application
indicates that a New Drug Application
for the human drug product atamestane
has been filed and is currently
undergoing regulatory review before the
Food and Drug Administration for
permission to market or use the product
commercially.
Review of the application indicates
that except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional period of
one year as required by 35 U.S.C.
156(d)(5)(C). Since it is apparent that
the regulatory review period will
continue beyond the extended
expiration date of the patent (June 18,
2005), interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,591,585 is granted for a period of one
year from the expiration date of the
patent, i.e., until June 18, 2006.
SUPPLEMENTARY INFORMATION:
Dated: May 26, 2005.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. 05–11175 Filed 6–3–05; 8:45 am]
BILLING CODE 3510–16–P
VerDate jul<14>2003
14:25 Jun 03, 2005
Jkt 205001
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. 2005–P–064]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,567,264;
Ranolazine
United States Patent and
Trademark Office.
ACTION: Notice of interim patent term
extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a third one-year interim extension of the
term of U.S. Patent No. 4,567,264.
FOR FURTHER INFORMATION CONTACT:
Karin Ferriter by telephone at (571)272–
7744; by mail marked to her attention
and addressed to Mail Stop Patent Ext.,
Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571)273–
7744; or by e-mail to
Karin.Ferriter@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 25, 2005, patent owner
Roche Palo Alto LLC, timely filed an
application under 35 U.S.C. 156(d)(5)
for a third interim extension of the term
of U.S. Patent No. 4,567,264. The patent
claims the active ingredient ranolazine
(RanexaTM). The application indicates,
and the Food and Drug Administration
(FDA) has confirmed, that a New Drug
Application for the human drug product
ranolazine has been filed and is
currently undergoing regulatory review
before the FDA for permission to market
or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional period of
one year as required by 35 U.S.C.
156(d)(5)(C). Since it is apparent that
the regulatory review period will
continue beyond the extended
expiration date of the patent (May 18,
2005), the term of the patent will be
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
32761
extended under 35 U.S.C. 156(d)(5) for
an additional year.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,567,264 is granted for an additional
period of one year from the extended
expiration date of the patent, i.e., until
May 18, 2006.
Dated: May 26, 2005.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. 05–11176 Filed 6–3–05; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: 2003–P–018]
Notice of Availability of and Request
for Comments on Green Paper
Concerning Restriction Practice
United States Patent and
Trademark Office, Commerce.
ACTION: Request for comments.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office (USPTO) has
established a 21st Century Strategic Plan
to transform the USPTO into a quality
focused, highly productive, responsive
organization supporting a market-driven
intellectual property system. As a part
of this plan, the USPTO is conducting
a study of its restriction practice. As
part of this study, the Office requested
public comments to help guide the
study. After careful consideration of the
public comments and an internal
review, the USPTO has prepared a
‘‘Green Paper’’ describing and
evaluating four options to reform
restriction practice suggested by various
members of the public. Prior to
considering the desirability of drafting
proposed legislation in a ‘‘White Paper’’
on reforming restriction practice, the
USPTO is seeking public comment on
the Green Paper.
DATES: Comment Deadline Date: To be
ensured of consideration, written
comments must be received on or before
August 5, 2005. No public hearing will
be held.
ADDRESSES: Comments should be sent
by electronic mail message over the
Internet addressed to:
unity.comments@uspto.gov. Comments
may also be submitted by mail
addressed to: Mail Stop Comments—
Patents, Commissioner for Patents, P.O.
Box 1450, Alexandria, VA, 22313–1450,
or by facsimile to (571) 273–7735,
marked to the attention of Robert A.
E:\FR\FM\06JNN1.SGM
06JNN1
]]>Agencies
[Federal Register Volume 70, Number 107 (Monday, June 6, 2005)]
[Notices]
[Page 32761]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-11176]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. 2005-P-064]
Grant of Interim Extension of the Term of U.S. Patent No.
4,567,264; Ranolazine
AGENCY: United States Patent and Trademark Office.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a third one-year interim
extension of the term of U.S. Patent No. 4,567,264.
FOR FURTHER INFORMATION CONTACT: Karin Ferriter by telephone at
(571)272-7744; by mail marked to her attention and addressed to Mail
Stop Patent Ext., Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450; by fax marked to her attention at (571)273-7744; or by
e-mail to Karin.Ferriter@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On March 25, 2005, patent owner Roche Palo Alto LLC, timely filed
an application under 35 U.S.C. 156(d)(5) for a third interim extension
of the term of U.S. Patent No. 4,567,264. The patent claims the active
ingredient ranolazine (RanexaTM). The application indicates,
and the Food and Drug Administration (FDA) has confirmed, that a New
Drug Application for the human drug product ranolazine has been filed
and is currently undergoing regulatory review before the FDA for
permission to market or use the product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for an additional period of one year
as required by 35 U.S.C. 156(d)(5)(C). Since it is apparent that the
regulatory review period will continue beyond the extended expiration
date of the patent (May 18, 2005), the term of the patent will be
extended under 35 U.S.C. 156(d)(5) for an additional year.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,567,264 is granted for an additional period of one year
from the extended expiration date of the patent, i.e., until May 18,
2006.
Dated: May 26, 2005.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. 05-11176 Filed 6-3-05; 8:45 am]
BILLING CODE 3510-16-P
